|1.||Villano, Stephen A: 3 articles (04/2011 - 05/2008)|
|2.||Townsend, Leroy B: 3 articles (05/2004 - 08/2002)|
|3.||Drach, John C: 3 articles (05/2004 - 08/2002)|
|4.||Ploy, M-C: 2 articles (01/2015 - 05/2013)|
|5.||Coen, Donald M: 2 articles (01/2015 - 01/2003)|
|6.||Hantz, S: 2 articles (01/2015 - 05/2013)|
|7.||Alain, S: 2 articles (01/2015 - 05/2013)|
|8.||Terhune, Scott S: 2 articles (11/2013 - 07/2013)|
|9.||Reitsma, Justin M: 2 articles (11/2013 - 07/2013)|
|10.||Villano, S A: 2 articles (11/2012 - 10/2009)|
01/01/2015 - "Notably, treatment of infected cells with the UL97 inhibitor maribavir or infection with a UL97 mutant led to a punctate rather than a continuous distribution of the NEC at the nuclear rim. "
01/01/2003 - "We used maribavir and a UL97 null mutant, which is severely deficient in viral replication, to determine what stage of virus infection critically requires UL97. "
01/01/2007 - "ViroPharma has conducted a dose-ranging phase II clinical study designed to evaluate the antiviral activity, safety and pharmacokinetic profile of maribavir for the prevention of CMV infection in patients who have undergone allogeneic stem cell transplantation. "
06/01/2008 - "Within the first 100 days after transplantation, the incidence of CMV infection based on CMV pp65 antigenemia was lower in each of the respective maribavir groups (15%, P = .046; 19%, P = .116; 15%, P = .053) compared with placebo (39%). "
01/01/2007 - "In February 2004, ViroPharma announced the initiation of a clinical programme to develop maribavir for prevention of CMV infection in transplant patients. "
01/01/2007 - "Glaxo was conducting phase I/II clinical studies in the EU and the US in 2001, but discontinued development because the company felt that there was no longer a significant clinical need for maribavir as advances in the treatment of HIV have lead to improved immune systems in patients, resulting in a reduction in the incidence of CMV and CMV retinitis. "
|3.||Epstein-Barr Virus Infections
|4.||Cytomegalovirus Infections (Inclusion Disease)
11/01/2011 - "Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection."
06/01/2008 - "Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study."
05/01/2013 - "Maribavir use in practice for cytomegalovirus infection in French transplantation centers."
12/01/2010 - "Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients."
07/01/2010 - "Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir."
10/01/2009 - "However, as seen with other maribavir studies, dysgeusia was common (90% of maribavir subjects and 20% of placebo subjects). "
05/01/2008 - "The most-common adverse event was dysgeusia (taste disturbance), reported by nine (47%) and seven (35%) subjects in the maribavir alone and maribavir-plus-ketoconazole groups, respectively. "
|4.||2- bromo- 5,6- dichloro- 1- ribopyranosyl- 1H- benzimidazole
|9.||DNA (Deoxyribonucleic Acid)
|1.||Transplantation (Transplant Recipients)
|2.||Stem Cell Transplantation